Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 17Phase 1/2 9Phase NA 5Phase 3 3Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Completed 59Unknown 12Terminated 7Active not recruiting 6Recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 42Stomach Neoplasms 35Neoplasm Metastasis 32Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

Vinblastine 2Doxorubicin 2Dacarbazine 2Bleomycin 2toripalimab 1pegfilgrastim 1Vincristine 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Etoposide 1Dexamethasone 1Cyclophosphamide 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Hodgkin Disease × Clear all
NCT04685616 2026-06-02

RADAR

University College, London

Phase 3 Recruiting
1,042 enrolled
Lymphoid

Hodgkin Disease

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Recruiting
185 enrolled
Lymphoid

Hodgkin Disease

NCT04638790 2024-09-27

HL-Russia-1

State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Phase 3 Recruiting
300 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡